Eli Lilly and Company cash flow to debt ratio of 39.56% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Eli Lilly and Company's free cash flow has increased 2.07K% from $414.30M last year to $8.97B, signaling increasing performance

Eli Lilly and Company's debt to equity ratio is 1.62, which means that the company's assets are unhealthy financed, signaling financial risk.

Eli Lilly and Company's debt has decreased relative to shareholder equity from 2.37 last year to 1.62 today, signaling strengthened financials

Eli Lilly and Company has a net debt to EBITDA ratio of 1.26x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Eli Lilly and Company's interest coverage ratio of 35.72 indicates that earnings with good margin can cover interest payments on company debt

Eli Lilly and Company's profit margin has increased (42.60%) in the last year from 23.51% to 33.53%, signaling increasing performance

Eli Lilly and Company's short-term assets of $55.63B exceed its short-term liabilities of $35.23B

Eli Lilly and Company's return on assets of 18.77% is higher than the 5.00% threshold, indicating efficient asset utilization

Eli Lilly and Company's return on equity of 92.58%, is higher than 15.00%, indicating good performance

Eli Lilly and Company's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Eli Lilly and Company had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Eli Lilly and Company has positive free cash flow, indicating the company generates cash after capital expenditures

Eli Lilly and Company has a free cash flow yield of 0.77%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Eli Lilly and Company's yearly earnings has increased 94.88% since last year from $10.59B to $20.64B, signaling increasing performance

Eli Lilly and Company's yearly revenue has increased 44.70% since last year from $45.04B to $65.18B, signaling increasing performance

ROIC 27.38% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Eli Lilly and Company's 3-year revenue CAGR of 31.69% is positive, indicating growing revenue over the past 3 years

Eli Lilly and Company had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Eli Lilly and Company had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Eli Lilly and Company is overvalued relative to its fair value price of 131.15 based on Discounted Cash Flow model

Eli Lilly and Company has an earnings yield of 2.43%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Eli Lilly and Company is overvalued relative to its fair value price of 169.58 based on EBITDA multiple model

Eli Lilly and Company has an EV/EBITDA ratio of 42.78x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Eli Lilly and Company is overvalued relative to its fair value price of 495.00 based on Earnings Fair Value model

Eli Lilly and Company has a PEG-ratio over 1 which is considered overvalued

Eli Lilly and Company has a price-to-book ratio of 32.44x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Eli Lilly and Company has a price-to-sales ratio of 13.80x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue